spironolactone has been researched along with nephrin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, M; Fukuda, S; Hayashi, M; Kawachi, H; Marumo, T; Monkawa, T; Saruta, T; Shimizu, F; Tsuji, M; Yoshino, J | 1 |
| Hamada, M; Hitomi, H; Imanishi, M; Kishida, M; Kobori, H; Konishi, Y; Maeda, I; Morikawa, T; Nagai, Y; Nakagawa, T; Nakano, D; Nishiyama, A; Ohashi, N; Okumura, M | 1 |
| Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K | 1 |
| Chen, C; Ding, G; Hu, F; Liang, W; Ren, Z; Shi, J; Singhal, PC; van Goor, H | 1 |
| Chen, YP; Cheng, H; Dong, HR; Dong, J; Liu, BL; Rui, HL; Yang, M; Zhu, JJ | 1 |
5 other study(ies) available for spironolactone and nephrin
| Article | Year |
|---|---|
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Monoclonal; Blood Pressure; Cilazapril; Drug Therapy, Combination; Fibrosis; Glomerulonephritis, Membranoproliferative; Kidney; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Proteinuria; Rats; Rats, Wistar; Spironolactone; Thy-1 Antigens | 2004 |
Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Drug Synergism; Eplerenone; Intracellular Signaling Peptides and Proteins; Kidney Glomerulus; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Rats; Rats, Inbred OLETF; Spironolactone; Telmisartan | 2010 |
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone; Fluorescent Antibody Technique; Intracellular Signaling Peptides and Proteins; Losartan; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Nephrosis, Lipoid; Podocytes; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Spironolactone; Time Factors | 2010 |
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Benzimidazoles; Benzoates; Blotting, Western; Calcium Channel Blockers; Eplerenone; Immunoenzyme Techniques; Kidney Glomerulus; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Telmisartan | 2011 |
Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes.
Topics: Aldosterone; Animals; beta Catenin; Disease Models, Animal; Down-Regulation; Eplerenone; Glomerulonephritis; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Kidney Cortex; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Obesity; Podocytes; Sialoglycoproteins; Spironolactone; Wnt Proteins; Wnt Signaling Pathway | 2018 |